 | | Vol. 11.47 – 11 December, 2020 |
| |
|
|
| Scientists demonstrated that selective agonists of Transient Receptor Potential cation channel subfamily M member 8, a cation channel characteristic of the prostate epithelium frequently overexpressed in advanced stage III/IV prostate cancers (PCa), sensitize therapy refractory models of PCa to radio, chemo or hormonal treatment.
[Cell Death & Disease] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| To identify genes that support enzalutamide resistance, researchers performed a short hairpin RNA screen in the bone-homing, castration-resistant prostate cancer cell line, C4-2B
[Molecular Cancer Therapeutics] |
|
|
|
| Representative in vitro model systems that accurately model response to therapy and allow the identification of new targets are important for improving the treatment of prostate cancer. Scientists described molecular characterization and drug testing in a panel of 20 prostate cancer cell lines.
[Scientific Reports] |
|
|
|
| Researchers analyzed the effect of tumor cell-free DNA, isolated from the blood of prostate cancer patients, on non-tumor prostate cell lines (RWPE-1 and PNT-2).
[Scientific Reports] |
|
|
|
| Investigators examined the effects of the inhibitor BTT‐3033, which selectively interferes with the connection between integrin a2b1 and its ligand, on migration, epithelial–mesenchymal transition, cell cycle arrest, apoptosis, and specific intracellular signaling pathways using LNcap‐FGC and DU‐145 prostate cancer cell lines.
[Journal of Cellular Physiology] |
|
|
|
| Examples of how polarized tris(2-pyridylmethyl)amine could be used to quantify freely available Zn2+ in homogenized human prostate tissue and intact cells were presented.
[Communications Chemistry] |
|
|
|
|
| Scientists focus on recent findings in cancer-associated genes and the application of short interfering RNAs (siRNAs) to successfully silence them in prostate cancer, as well as recent progress for effectual delivery of siRNAs to cancer cells.
[Cancers] |
|
|
|
| The effects and molecular mechanisms of ASC‐J9 on various androgen receptor‐associated diseases are summarized. Importantly, the effects of ASC‐J9 and AR antagonists enzalutamide/bicalutamide on prostate cancer are compared in detail and crucial differences are highlighted.
[Chemical Biology & Drug Design] |
|
|
|
|
| Harpoon Therapeutics, Inc. has provided a pipeline update and reported a confirmed partial response based on RECIST v1.1 criteria for its most advanced program, HPN424 for the treatment of metastatic castration-resistant prostate cancer. In the 160ng/kg cohort, which is the highest fixed dose tested to date, seven patients have been enrolled and one patient has achieved a confirmed partial response.
[Harpoon Therapeutics, Inc.] |
|
|
|
|
| January 15 – 16, 2021
Virtual |
|
|
|
|
|
| | Scripps Research Institute – La Jolla, California, United States |
|
|
|
| | Pfizer – La Jolla, California, United States |
|
|
|
| | University of Cincinnati – Cincinnati, Ohio, United States |
|
|
|
| | NIH National Cancer Institute – Bethesda, Maryland, United States |
|
|
|
| | The University of Texas MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
